Tadalafil (C6)
tuh-FAD-uh-le
Category
Compound type
Phase / Status
FDA approved (brand name Cialis). Generic available. Commonly used ED/BPH medication.
Standard Dose
As needed or 2.5-5mg daily
Half-life
Plasma elimination
Route(s)
Oral
Research Stage
Regulatory approval granted; post-market monitoring ongoing.
Overview
Tadalafil is often described as a longer-lasting ED option. Compared with shorter-acting medications like sildenafil, its effects can last closer to a day (sometimes longer). It supports erections by improving blood flow.
Plain-language summary
Tadalafil is often described as a longer-lasting ED option. Compared with shorter-acting medications like sildenafil, its effects can last closer to a day (sometimes longer). It supports erections by improving blood flow.
Administration Routes
- Oral
Also known as
Mechanisms
Phosphodiesterase type 5 (PDE5) inhibitor. It relaxes blood vessels and improves blood flow.
Detailed mechanism
Phosphodiesterase type 5 (PDE5) inhibitor - increases blood flow by relaxing blood vessels. It works through cellular signaling that affects smooth muscle tone, leading to therapeutic effects.
Safety
Side effects
- Headache
- Back pain
- Muscle aches
- Nasal congestion
- Flushing
- Rare vision changes
Reported benefits
- Long duration of action (often up to 36 hours)
- Treats erectile dysfunction
- Increases blood flow
- May help with exercise-related "pumps" (varies)
- Often well-tolerated
- Daily low-dose option available for some indications
Safety profile
Well-characterized safety profile from extensive clinical use and trials. Seek medical advice for contraindications and drug interactions.
Clinical trials
Completed clinical trials leading to FDA or regulatory approval.
Structure
Verified structure
Tadalafil (C6)
No exact public structure match was confirmed, so the app will render a formula-backed illustration.
- Chemical Formula
- C22H30N6O4
- Molecular Weight
- 389.46 g/mol
- CAS Number
- 171596-29-3
Stack Context
Stacks with
References
- 1View source
Tadalafil (Cialis) FDA drug approval record - NDA 021368 (U.S. FDA Center for Drug Evaluation and Research)
2003
- 2View source
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: a Phase 3 randomized placebo-controlled trial (BJU International)
2003
- 3View source
Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis (European Urology)
2012
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.